35717-98-7

Basic information

• Product Name: (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE
• Synonyms: (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE;[[[(4-Methylphenyl)sulfonyl]oxy]methyl]phosphonic acid bis(isopropyl) ester;Diisopropyl [(p-tolylsulfonyl)oxy]methanephosphonate;(Diisopropoxyphosphoryl)Methyl 4-Methylbenzenesulfonate [[[(4-Methylphenyl)sulfonyl]oxy]Methyl]phosphonic acid;bis(isopropyl) ester
• CAS NO: 35717-98-7
• Molecular Formula: C₁₄H₂₃O₆PS
• Molecular Weight: 350.37
• Mol File: 35717-98-7.mol

Chemical Properties

• Boiling Point: 454.3±28.0 °C(Predicted)
• Appearance: /
• Density: 1.206
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE(35717-98-7)
• EPA Substance Registry System: (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE(35717-98-7)

Safety Data

• Hazardous Substances Data: 35717-98-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE is used as a coupling reagent for peptide and protein synthesis, facilitating the formation of amide bonds and contributing to the development of novel bioactive compounds and pharmaceuticals.
Used in Prodrug Preparation:
In the pharmaceutical industry, (DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE is utilized as a key component in the preparation of phosphoramidate prodrugs, enhancing the drug's stability and bioavailability, particularly for drugs that are prone to hydrolysis.
Used in Organic Synthesis:
(DIISOPROPOXYPHOSPHORYL)METHYL 4-METHYLBENZENESULFONATE serves as an important intermediate in organic synthesis, enabling the creation of a wide range of chemical compounds and contributing to advancements in various fields of chemistry.

Upstream product

• 24630-68-0 diisopropyl hydroxymethylphosphonate 
• 98-59-9 p-toluenesulfonyl chloride 
• 691-96-3 diisopropyl phosphite 
• 1809-20-7 diisopropyl hydrogenphosphonate 

Downstream Products

• 168975-75-5 2-chloro-4-cyclopropylpyridine 
• 186593-59-9 (2-Benzyloxy-1-hydroxymethyl-ethoxymethyl)-phosphonic acid diisopropyl ester 

Relevant articles and documents

THYROID HORMONE RECEPTOR AGONIST AND USE THEREOF

A thyroid hormone receptor agonist and its use in the treatment of a disease associated thyroid hormone receptor beta are described. The compound can be effective in lowering cholesterol with minimum or no adverse effects on the heart or thyroid hormone axis.

PHOSPHORUS-CONTAINING THYROID HORMONE RECEPTOR AGONISTS AND METHODS OF USE

The present invention relates to sulfonic acid containing compounds that bind to thyroid receptors in the liver. Activation of these receptors results in modulation of gene expression of genes regulated by thyroid hormones. The compounds can be used to treat diseases and disorders including metabolic diseases such as NASH, hypercholesterolemia and hyperlipidemia, as well as associated conditions such as atherosclerosis, coronary heart disease, impaired glucose tolerance, and metabolic syndrome X.

Synthesis of cyclopropane-containing phosphorus compounds by radical coupling of butenylindium with iodo phosphorus compounds

The radical coupling of α- or β-iodo phosphorus compounds such as iodo phosphonate, iodo phosphane oxide, and iodo phosphonothioate with butenylindium species, prepared by transmetalation between a (cyclopropylmethyl)stannane and InBr3, afforded the corresponding cyclopropylmethylated products. The radical reaction was initiated by the radical species generated from butenylindium assisted by a small amount of oxygen. Butenylindium works not only as a cyclopropylmethylating reagent, but also as a radical initiator. For successful coupling, a tin/indium transmetalation was used, where it was important for the tin halide by-product to be inert to the reaction system. In addition, the transmetalation of a (cyclopropylmethyl)stannane and InBr3 provided the dibutenylindium bromide as a single product, which smoothly coupled with the unstable phosphonyl radical species from the iodo phosphorus compound. A photochemical method (UV irradiation) was also applied and accelerated the coupling reaction. The cyclopropylmethylated phosphonate produced was a good intermediate in the Horner-Wadsworth-Emmons reaction and gave functionalized olefins bearing the cyclopropane moiety. Copyright

SYNTHESES OF ENANTIOMERIC N-(3-HYDROXY-2-PHOSPHONOMETHOXYPROPYL)DERIVATIVES OF PURINE AND PYRIMIDINE BASES

Methods of preparation of N-(3-hydroxy-2-phosphonomethoxypropyl) (HPMP) derivatives of (2S)- and (2R)-configuration compounds I and XXVII, respectively are described.The general method starts from the corresponding N-(2,3-dihydroxypropyl) derivatives which were converted either into the (R)-enantiomers XIII by reaction of the base with (R)-glycidol butyrate (XII) in the presence of cesium carbonate and subsequent methanolysis, or into the (S)-enantiomers XI by alkylation of the base with (R)-2,2-dimethyl-4-tosyloxymethyl-1,3-dioxolane (V) in the presence of the same reagent.The amino groups on the heterocyclic base in compounds XI and XIII were benzoylated by silylation followed by reaction with benzoyl chloride and the obtained N-benzoates XV and XVII on reaction with trityl chloride afforded the corresponding 3'-O-trityl derivatives XVI and XVIII.These compounds were condensed with bis(2-propyl)-p-toluenesulfonyloxymethanephosphonate (XXIII) in dimethylformamide in the presence of sodium hydride to give the fully protected diesters XXIV and XXVIII.These compounds could be selectively acid-hydrolyzed to remove the trityl group only under formation of compounds XXXV, or methanolyzed and then acid-hydrolyzed to remove the trityl and N-benzoyl groups and lead to compounds XXVI and XXX, or treated with bromotrimethylsilane to remove the trityl and 2-propyl group to give phosphonates of the type XXVI.All the three types of compounds were then converted into free phosphonates of the (S)-series (I) and (R)-series (XXVII).Derivatives of cytosine (Ia, XXVIIa), adenine (Ib, XXVIIb), 2,6-diaminopurine (Ic, XXVIIc) and guanine (Id, XXVIId) were prepared.Condensation of the partially blocked adenine derivative XXXV with the tosyl derivative XXIII and subsequent deprotection afforded 9-(S)-(2,3-diphosphonomethoxypropyl)adenine (XLIII).Reaction of the same compound XXXV or its (R)-enantiomer XXXVIII with diethyl chlorophosphonate, followed by deblocking, afforded 3'-O-phosphoryl derivatives (S)-HPMPA (XXXVII) and (R)-HPMPA (XL).

9-[(Phosphonoalkyl)benzyl]guanines. Multisubstrate analogue inhibitors of human erythrocyte purine nucleoside phosphorylase

A series of 9-[(phosphonoalkyl)benzyl]guanines was synthesized and tested for inhibition of human erythrocyte purine nucleoside phosphorylase (PNPase). Inhibitors of PNPase should be T-cell selective, immunosuppressive agents with potential clinical utili

Biosynthesis of Naturally Products with a P-C Bond. Part 6. Preparation of Deuterium- and Carbon-13-Labelled L-Alanyl- and L-Alanyl-L-alanyl-(2-aminoethyl)phosphonic Acids and their Use in Biosynthetic Studies of Fosfomycin in Streptomyces fradiae

(2-Aminoethyl)phosphonic acid (AEP) is not taken up by Streptomyces fradiae in the biosynthesis of fosfomycin.Attachment of L-alanine or L-alanyl-L-alanine to the amino group of deuteriated AEP affords di- and tri-peptides 4 and 5 which are transported into the cell. AEP is synthesized from Na(13)CN and the tosyloxymethylphosphonate 7.It is transformed into dipeptide 4d, which acts as a carrier for AEP which is incorporated into fosfomycin with an enrichment of 2 percent.

Antiretroviral bases

The present invention relates to N-(3-fluoro-2-phosphonylmethoxypropyl) derivatives of purine and pyrimidine heterocyclic bases, useful against retroviruses.